
Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Austrian Kern Tec raises €12m in Series A financing
Food tech specialist Kern Tec GmbH (Vienna) will use €12m from a €12m Series financing to scale up manufacturing of dairy products from upcycled...

Breakthrough in COPD treatment
Sanofi's duplimab (Dupixent®) showcased notable efficacy in reducing exacerbations and enhancing lung function in its second positive Phase III...